文献速递呼吸衰竭与机械通气儿科与产科急症

婴儿期呼吸道合胞病毒预防与6岁前鼻咽部微生物群:MAKI随机对照试验的子分析

Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
PubMed 文献 · Lancet Respir Med · 2020-03-20
一句话结论健康早产儿婴儿期使用帕利珠单抗预防呼吸道合胞病毒,与1岁时鼻咽部微生物群组成改变相关,6岁时部分微生物丰度变化持续存在,且与可逆性气道阻塞相关。

MAKI试验是一项多中心、单盲、随机、安慰剂对照试验,纳入胎龄32-35周的健康早产儿,在第一个呼吸道合胞病毒流行季随机接受帕利珠单抗15 mg/kg或安慰剂肌内注射。本子分析对1岁和6岁时鼻咽拭子行16S-rRNA测序,主要终点为婴儿期帕利珠单抗对1岁和6岁时呼吸道微生物群组成的影响。1岁时帕利珠单抗组与安慰剂组整体微生物群组成显著不同(R2 1.3%;p=0.0185),帕利珠单抗组葡萄球菌主导集群丰度显著降低(OR 0.28,95%CI 0.11-0.68;p=0.00394)。6岁时整体组成无显著差异(R2 0.6%;p=0.0575),但帕利珠单抗组嗜血杆菌属丰度增加、莫拉菌属和奈瑟菌科丰度降低。6岁时可逆性气道阻塞与嗜血杆菌属丰度正相关,与莫拉菌属、棒状杆菌属、Dolosigranulum和葡萄球菌属等健康相关分类群丰度负相关。

要点

  • 健康早产儿婴儿期帕利珠单抗预防后,1岁时鼻咽部葡萄球菌主导集群丰度显著低于安慰剂组(OR 0.28,95%CI 0.11-0.68;p=0.00394)。
  • 6岁时两组整体微生物群组成无显著差异(R2 0.6%;p=0.0575),但帕利珠单抗组嗜血杆菌属丰度增加、莫拉菌属和奈瑟菌科丰度降低。
  • 1岁时无PCR确诊RSV感染与6岁时嗜血杆菌属高丰度及莫拉菌属、奈瑟菌科低丰度显著相关。
  • 6岁时可逆性气道阻塞与嗜血杆菌属丰度正相关,与莫拉菌属、棒状杆菌属、Dolosigranulum和葡萄球菌属丰度负相关(均p<0.05)。
  • 作者认为这些结果需进一步研究以确定婴儿期帕利珠单抗的长期生态效应和健康后果。

适用人群与场景

  • 胎龄32-35周的健康早产儿,在第一个RSV流行季开始时月龄≤6个月。
  • 排除标准包括先天性心脏病、支气管肺发育不良、唐氏综合征或其他严重先天性疾病、出生时使用机械通气、使用肺表面活性物质、或RSV流行季开始前医生诊断的喘息。
  • 多中心研究,纳入荷兰1所大学医院和15所地区医院。

处置流程与药物剂量

  • 帕利珠单抗15 mg/kg或安慰剂肌内注射,在一个RSV流行季内给药:从10月1日或从新生儿病房出院时至3月10日,最少2次、最多5次注射。

研究设计与关键结果

  • 多中心、单盲、随机、安慰剂对照试验(MAKI试验)子分析,2008年4月1日至2010年12月31日共纳入429例婴儿(帕利珠单抗组n=214,安慰剂组n=215)。
  • 1岁时从429例中采集170例(40%)拭子并测序,其中145例(85%)样本DNA质量高;帕利珠单抗组与安慰剂组整体微生物群组成显著不同(R2 1.3%;p=0.0185),帕利珠单抗组葡萄球菌主导集群丰度显著降低(OR 0.28,95%CI 0.11-0.68;p=0.00394),克雷伯菌属等生物标志物种丰度增加,口腔分类群(包括链球菌属)多样性增加。
  • 6岁时从完成随访的395例中采集349例(88%)拭子并测序,其中342例(98%)样本DNA质量高;两组整体微生物群组成无显著差异(R2 0.6%;p=0.0575),但帕利珠单抗组嗜血杆菌属丰度显著增加,莫拉菌属和奈瑟菌科丰度降低。
  • 1岁时无PCR确诊RSV感染与6岁时嗜血杆菌属更高丰度及莫拉菌属、奈瑟菌科更低丰度显著相关。
  • 6岁时可逆性气道阻塞与嗜血杆菌属丰度正相关,与莫拉菌属、棒状杆菌属、Dolosigranulum和葡萄球菌属等健康相关分类群丰度负相关(均p<0.05),校正RSV免疫预防后仍显著;可逆性气道阻塞还与肺炎链球菌丰度显著升高相关。

证据类型、等级与局限

  • 证据类型:多中心、单盲、随机、安慰剂对照试验的子分析。
  • 局限:原文报告需进一步研究以确定婴儿期帕利珠单抗的长期生态效应和健康后果。

对床旁实践的改变

  • 作者认为这些结果需进一步研究以确定婴儿期帕利珠单抗的长期生态效应和健康后果。

指南或共识出处

  • MAKI随机对照试验(ISRCTN73641710),资助方MedImmune。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Respiratory syncytial virus (RSV) infection during infancy is suggested to cause long-term wheeze. In turn, wheeze has been associated with bacterial dysbiosis of the respiratory tract. We investigated the effects of RSV prophylaxis with palivizumab in otherwise healthy preterm infants on respiratory microbiota composition at 1 year and 6 years of age.

METHODS: In a multicentre, single-blind, randomised, placebo-controlled trial (the MAKI trial), infants born between 32-35 weeks of gestation, in one university and in 15 regional hospitals in the the Netherlands, were randomly assigned (1:1) to receive palivizumab or placebo during the RSV season of their first year of life. Intramuscular injections of palivizumab 15 mg/kg or placebo were given during one RSV season: either from Oct 1, or from discharge from the neonatal unit until March 10 (minimun of 2 and maximum of 5 injections were given). Children were 6 months old or younger at the start of the RSV season; exclusion criteria included congenital heart disease, bronchopulmonary dysplasia, Down's syndrome, or other serious congenital disorders, use of mechanical ventilation at birth, treatment with surfactant, or physician-diagnosed wheeze before the start of the RSV season. Children were followed up for clinical symptoms until 6 years of age. For this subanalysis, we obtained nasopharyngeal swabs from children aged 1 year and 6 years and analysed them using 16S-rRNA sequencing. At 6 years we also measured reversible airway obstruction. The primary outcome was the effect of palivizumab during infancy on the respiratory microbiota composition at age 1 year and 6 years (intention-to-treat analysis). The trial is registered in the ISRCTN registry, number ISRCTN73641710.

FINDINGS: From April 1, 2008, to Dec 31, 2010, 429 infants were enrolled in the MAKI trial (n=214 to the palivizumab group; n=215 to the placebo group). At 1 year, we collected swabs and sequenced DNA from 170 (40%) of 429 children, of which 145 (85%) samples had high-quality DNA. The overall microbiota composition was significantly different (R2 1·3%; p=0·0185) between the palivizumab group and the placebo group at 1 year of life; children in the palivizumab group had a significantly lower abundance of the Staphylococcus-dominated cluster (odds ratio 0·28 [95% CI 0·11-0·68]; p=0·00394), an increased abundance of biomarker species, such as Klebsiella, and a more diverse set of oral taxa, including Streptococcus spp, compared with children in the placebo group. At 6 years, we collected swabs and sequenced DNA from 349 (88%) of 395 children who completed follow-up, of which 342 (98%) samples had high-quality DNA. The overall microbiota composition was not significantly different between groups at 6 years (R2 0·6%; p=0·0575); however, children in the palivizumab group had a significantly increased abundance of Haemophilus spp and lower abundance of Moraxella and Neisseriaceae spp compared with children in the placebo group. Absence of PCR-confirmed RSV infection at 1 year was significantly associated with a higher abundance of Haemophilus spp at age 6 years and a significantly lower abundance of Moraxella and Neisseriaceae than children with RSV infection at 1 year. Reversible airway obstruction at 6 years was also positively associated with Haemophilus abundance and negatively associated with the abundance of health-associated taxa, such as Moraxella, Corynebacterium, Dolosigranulum, and Staphylococcus, even after correction for RSV immunoprophylaxis (all: p<0·05). Additionally, reversible airway instruction was associated with significantly higher Streptococcus pneumoniae abundance.

INTERPRETATION: Palivizumab in infancy in otherwise healthy preterm infants is associated with persistent effects on the abundance of specific, potentially pathogenic, microbial taxa in the respiratory tract. Several of the palivizumab-associated biomarker species were associated with reversible airway obstruction at age 6 years. These results warrant further studies to establish the long-term ecological effects and health consequences of palivizumab in infancy.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Man WH, Scheltema NM, Clerc M, et al. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial. Lancet Respir Med. 2020. PMID: 32203712. doi:10.1016/S2213-2600(19)30470-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。